Literature DB >> 8346921

Ascorbic acid inhibition of cytochrome P450-catalyzed uroporphyrin accumulation.

P R Sinclair1, N Gorman, H S Walton, W J Bement, J M Jacobs, J F Sinclair.   

Abstract

Previous studies on the mechanism of the uroporphyria caused by polyhalogenated aromatic hydrocarbons have indicated a key role of cytochrome P450 of the 1A subfamily in catalyzing uroporphyrinogen (UROgen) oxidation. Here we report that ascorbic acid (ASC) inhibits UROgen oxidation in primary cultures of chick embryo hepatocytes and hepatic microsomes from chickens and mice. In hepatocyte cultures, 0.15 mM ASC totally prevented the accumulation of uroporphyrin (URO) induced by treatment of cells with the combination of 3,4,3',4'-tetrachlorobiphenyl (TCB) and 2-propyl-2-isopropylacetamide (PIA), but had no effect on the induction of protoporphyrin accumulation by PIA and desferrioxamine. However, addition of 5-aminolevulinic acid (ALA) to cultures treated with PIA plus TCB decreased the ability of ASC to prevent URO accumulation, suggesting that the effectiveness of ASC was dependent on the intracellular concentration of ALA or its metabolites. Similarly, when chick hepatocyte cultures were treated with TCB plus exogenous ALA to produce URO accumulation, the effectiveness of ASC was also less than when ALA was produced endogenously. Under this condition, addition of piperonyl butoxide, a P450 inhibitor, increased ASC inhibition of URO accumulation. ASC competitively inhibited the oxidation of UROgen by hepatic microsomes from chicks or mice treated with 3-methylcholanthrene (MC) with Ki for ASC being about 0.1 mM. ASC prevented formation of a 500-nm absorbing compound, probably tetrahydrouroporphyrin, the first intermediate in UROgen oxidation. These results are consistent with ASC preventing URO accumulation in hepatocytes by competitive inhibition of the first step of UROgen oxidation and suggest a new physiological role of ASC, that of maintaining UROgen in the reduced state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346921     DOI: 10.1006/abbi.1993.1376

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  5 in total

1.  Turnabout is fair play: Secondary roles for primary compounds.

Authors:  M R Berenbaum
Journal:  J Chem Ecol       Date:  1995-07       Impact factor: 2.626

2.  NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid.

Authors:  M K Ghosh; M Mukhopadhyay; I B Chatterjee
Journal:  Mol Cell Biochem       Date:  1997-01       Impact factor: 3.396

3.  Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.

Authors:  Norman G Egger; Douglas E Goeger; Deborah A Payne; Emil P Miskovsky; Steven A Weinman; Karl E Anderson
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

4.  A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda.

Authors:  John D Phillips; Hector A Bergonia; Christopher A Reilly; Michael R Franklin; James P Kushner
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-09       Impact factor: 11.205

Review 5.  Role of Vitamin C in Skin Diseases.

Authors:  Kaiqin Wang; Hui Jiang; Wenshuang Li; Mingyue Qiang; Tianxiang Dong; Hongbin Li
Journal:  Front Physiol       Date:  2018-07-04       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.